Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Sirona Biochem is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Sirona Biochem has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Sirona Biochem. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Sirona Biochem's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sirona Biochem has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Sirona Biochem's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Sirona Biochem's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Sirona Biochem's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Sirona Biochem is high growth as no earnings estimate data is available.
Unable to determine if Sirona Biochem is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Sirona Biochem's filings and announcements here.
Sirona Biochem's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Howard J. Verrico, M.D., Ph.D, is the Founder of Sirona Biochem Corp., has been Chief Executive Officer since June 18, 2014 and serves as its Secretary. Dr. Verrico served as the Chief Executive Officer of Sirona Biochem Corp. until October 2012 and its Interim President from December 16, 2011 to October 2012. He is a practicing physician working in both emergency and general practice in the province of British Columbia. He served as President of High Rider Capital Inc. until April 29, 2009. Dr. Verrico served as Secretary and Chief Executive Officer of Consolidated Ecoprogress Technology Inc from October 2002 to March 2004. Dr. Verrico has extensive experience as an investor in the junior capital markets providing both venture capital loans and a number of private placements. He serves as the Chairman of Sirona Biochem Corp. and has been its Director since September 19, 2006. He served as Director of Consolidated Ecoprogress Technology Inc from October 2002 to March 2004. Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a Member of the College of Physicians and Surgeons of British Columbia since July 1986.
Howard's compensation has increased whilst company is loss making.
Howard's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Sirona Biochem management team is over 5 years, this suggests they are a seasoned and experienced team.
CFO & Director
Chief Scientific Officer & Director
Vice President of Operations
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Sirona Biochem board of directors is about average.
Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada and France. The company develops programs in three areas, including diabetes, anti-inflammatories, and anti-infectives for therapeutics; anti-aging and depigmenting agents in cosmeceuticals; and biological ingredients, such as inducers and adjuvants for the biological development and preservation. It develops a sodium glucose co-transporter inhibitor for the treatment of diabetes, as well as cosmetic skin lightening agents and compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.